Lake Zurich, Ill., June 1, 2015 – Fresenius Kabi, a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition, announced today the immediate availability of Argatroban Injection in the U.S.
Argatroban Injection is an anticoagulant indicated for prophylaxis or treatment of thrombosis in adult patients with heparin induced thrombocytopenia (HIT), or as an anticoagulant in adult patients with or at risk for HIT undergoing percutaneous coronary intervention.
Fresenius Kabi Argatroban is available in a 250mg/2.5mL presentation in a single dose vial and was approved by the FDA in March 2015.
“Fresenius Kabi has a broad and expanding portfolio of critical care medicines, and with just a few manufacturers supplying Argatroban today, our launch gives health care providers a new source for this important drug,” said John Ducker, president and CEO of Fresenius Kabi USA.
About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.us) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany.
For more information about Fresenius Kabi worldwide, please visit www.fresenius-kabi.com.